The invention relates to the novel dihydrothienopyrimidine sulfoxides of formula and to the pharmacologically acceptable salts thereof, wherein X represents SO or SO2, preferably however SO, and wherein R3, R4, R4\u2032, R5, R6 and R7 are defined as in claim 1. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta inhibitors, and to methods for regulating angiogenesis. The cavities can be both optically and electrically pumped. Side edges of the front end portion opposed to each other in the transverse direction are formed with front side corner regions and side edges of the rear end portion opposed to each other in the transverse direction are formed with rear side corner regions.